Skin biopsies could unlock secrets of ALS
NCT ID NCT06450691
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study takes skin biopsies and blood samples from people with ALS, healthy carriers of ALS-related gene mutations, and control subjects. Researchers will grow skin cells in the lab to study how the disease works at a cellular level. The goal is to better understand ALS, not to test a new drug or treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help scientists better understand how ALS develops and progresses, potentially pointing toward future targets for therapy.
- What could go wrong
- This is an observational study, not a treatment trial. It is early-stage research that may not directly lead to new treatments or benefit participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Sep 2034
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria common to all 3 populations: * adults, both sexes * with written consent to participate in the study * affiliated to a social security scheme ALS patients : * patients with ALS according to the revised El Escorial criteria : * with a hereditary form of ALS, defined by the presence of a family history of ALS or by the demonstration of a pathogenic mutation in the patient or * with a juvenile form of the disease, defined by onset of symptoms at less than 30 years of age or * with a sporadic form of ALS Asymptomatic mutation carriers : \- Asymptomatic individuals who carry a mutation causing ALS but have not developed symptoms. Healthy subjects: * control individuals, taking into account male/female and close age matching Exclusion Criteria: * with a known skin disease (acne, atopic dermatitis, psoriasis, melanoma, skin carcinoma, rosacea, scabies; as referenced on http://dermato-info.fr/), which in the investigator's opinion constitutes a contraindication to skin biopsy * have a platelet count of less than 75,000/mm3 in a laboratory test less than 3 months old, * with a proven allergy to lidocaine or prilocaine, * Pregnant or breast-feeding women, or subjects under guardianship, curatorship or safeguard of justice. * Patient's condition which, in the opinion of the investigator, is incompatible with skin sampling or participation in the study. * Participation in a clinical trial (involving a drug) or other interventional research if this interferes with FIBRALS research.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CIC Neurosciences
RECRUITINGParis, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing device tested to slow lung decline in ALS
- Can hospital codes reliably track home ventilation in ALS?
- Can a synthetic compound be safe enough to test in ALS? early trial asks
- Can a cheap gout drug slow ALS? trial puts colchicine to the test
- Can donor gut bacteria reshape the immune system in ALS?
- Spinal injection drug targets genetic cause of ALS and dementia